• News
  • SAN DIEGO
  • Health

BioAtla licenses antibody rights to BioMotiv

BioAtla has licensed exclusive worldwide rights to develop and commercialize its TH22 pathway-directed antibody compound for the treatment of inflammatory bowel diseases and oncologic indications to BioMotiv.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments
Subscribe Today!